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Introduction
Epidermis, the outermost layer of skin, deploys an epidermal 
permeability barrier to prevent excess water loss1 and ingress of 
pathogens, allergens and xenotoxic agents.2 The presence of this 
barrier is necessary for survival of mammalian species in a terres-
trial environment. More precisely, lipid lamellar membrane struc-
tures in the extracellular domain of the stratum corneum (SC) are 
responsible for barrier function. Heterogeneous molecular species 
of ceramide (Cer) are key constituents that form lamellar struc-
tures. The most unique and essential Cer species contain very 
long omega (ω)-hydroxy fatty acids (ω-OH VLCFA) (hydrocar-
bon chain length ranging from 28–34). Such very long chain 
lengths of fatty acids (VLCFA) have been found in selected tis-
sues, such as retina,3 brain,4 testis,5 spermatozoa6 and epidermis 
(reviewed in ref. 7), while ω-OH VLCFA as well as Cer and their 
glucosylated counterparts containing ω-OH VLCFA have been 
found only in differentiated layers of the epidermis of terrestrial 
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Heterogeneous molecular species of epidermal ceramide (Cer) 
play critical roles in forming a competent permeability barrier of 
lamellar membrane structures in the stratum corneum, which 
is a prerequisite to preventing excess water loss for terrestrial 
mammals. Lipids containing very long chain lengths of fatty 
acids (vLCFA) (hydrocarbon chain lengths over 28) have been 
found in selected tissues, including epidermis. in particular, 
ω-hydroxy (ω-OH) vLCFA as well as Cer containing ω-OH 
vLCFA and ω-O-acylCer (acylCer) are unique to epidermis. 
The fatty acid elongation system that generates vLCFA, which 
requires four enzymatic steps, has been characterized, while 
recent studies using transgenic animals have further revealed 
the importance of ω-OH Cer species for barrier formation and 
have also elucidated the synthetic pathway of these essential 
Cer species in conjunction with vLCFA metabolism. This 
review article discusses the generation of vLCFA and unique 
epidermal Cer species containing vLFCA in the relation to their 
roles in epidermis.
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mammals. This review article describes the generation and roles 
of VLCFA in epidermis.
Note. FA are generally classified into Short chain fatty acid 
(SCFA), containing fewer than six chain lengths of hydrocar-
bons, Medium chain fatty acid (MCFA) with 6–12 hydrocarbons, 
Long chain fatty acid (LCFA) with longer than 12 hydrocarbons, 
and VLCFA with longer than 22. In this review article, VLCFA 
indicates FA containing longer than 28 hydrocarbons.
VLCFA Biosynthesis
Lipids are divided into neutral lipids and complex lipids. Fatty 
acids (FA) are constituents of both of these lipid species. Neutral 
lipids are generated from alcohol and FA, i.e., acylglyceride (glyc-
erol + FA), wax (primary alcohol + long chain FA), Cer (long 
chain amino alcohol + FA) and sterol esters (sterol + FA). Complex 
lipids include phospholipids and glycolipids, which contain either 
a glycerol or sphingoid base (long chain amino alcohol) backbone 
structure, respectively. FA serve as a major source of energy as 
well as structural components of membranes as both free forms 
and esterified forms, and also act as nuclear hormone ligands to 
regulate cellular functions.
FA with carbon chain lengths up to C16 are synthesized by 
the FA synthase complex localized in cytosolic fraction (FAS-I) 
and mitochondria (FAS-II)8 (c.f. see in the review of this series by 
Dr. Denis Khnykin). Synthesized FA or FA supplied from dietary 
sources are then elongated by membrane-associated FA chain-
elongation system at the endoplasmic reticulum (ER).8 Similar 
to the FA synthase complex, the FA chain-elongation system uses 
four metabolically-linked enzymes for chain elongation: 3-keto-
acyl-CoA synthase (Condensation), 3-keto-acyl-CoA reductase 
(Reduction), 3-hydroxyacyl-CoA hydrase (Dehydration) and 
2,3 enoyl-CoA reductase (Reduction). Chain extension occurs 
via two carbons per cycle. While the fatty acid synthase (FAS-I) 
is a single, homodimeric, multifunctional protein, both the FA 
elongation complex and FAS-II consist of four different classes 
of enzymes.
The enzymes that catalyze these four steps have been recently 
characterized in mammals.
(1) Condensation (1st Step). ELOs that are responsible for the 
condensation step first were found in yeasts, and later in plants 
and mammals. Seven ELO homologues (ELOVL 1–7) have 
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specific distribution.15 While the expression profile of ELOVL7 
has not been elucidated, distribution of the other six ELOVL 
have been examined, i.e., ELOVL1, ELOVL5 and ELOVL6 are 
ubiquitously expressed, while ELOVL2, ELOVL3 and ELOVL4 
highly express in liver/testis, skin/liver and retina/brain/skin, 
respectively (note: whole skin was used in this study).24 Yet, the 
expression profile/level of other ELOVLs has not been completely 
defined in comparison to other tissues.
ELOVLs contain five transmembrane regions, a histidine-rich 
motif (HXXHH) and a ER retention signal (KKXX) (reviewed 
in ref. 7).
The distinctive roles of each ELOVL in generating different 
VLCFA species have been elucidated, while recent studies using 
different chain lengths of FA as substrates further clarified the 
substrate specificities and their products.15 ELOVL1, ELOVL3, 
ELOVL4 and ELOVL6 account for the elongation of both 
saturated and monosaturated VLCFA synthesis, i.e., ELOVL1, 
substrate specificity: C20-26, C20-22:1; ELOVL3, C18-26, 
C20-22:1; and ELOVL6, C12-16, C18:1, while ELOVL2 and 
ELOVL5 elongate polyunsaturated FA (PUFA), i.e., C20-22:4, 
C20-22:5 and ELOVL5, C18-20:4, C20:5.15 ELOVL4 utilizes 
both saturated and PUFA as substrates (≥C24, C24:4, C24:5, 
C24:6) to synthesize VLCFA.15
Roles of VLCFA in Epidermis
In addition to free VLCFA form, VLCFA are utilized as constitu-
ents of amide-like FA in Cer and GlcCer in epidermis. In par-
ticular, acylceramides (acylCer) (Fig. 1) and their glucosylated 
form [acylglucosylceramide (acylGlcCer)] that contain ω-OH 
VLCFA are unique to epidermis. Moreover, ω-OH residue is 
esterified by the predominantly essential FA, linoleate, deficiency 
of which results in abnormal permeability function.16 Therefore, 
roles of acylCer and acylGlcCer in skin have been paid attention 
to since the discovery of these molecules in the early 1980s,17-
19 and the importance of acylCer as an epidermal permeability 
barrier constituent has mounted. In vitro studies using recon-
stituted membrane models demonstrated the role of acylCer in 
the establishment of the long periodicity phase (13 nm) that 
represents normal lamellar membrane structures in the extracel-
lular domains of barrier competent SC.20 Indeed, decreases in 
acylCer have been shown in cutaneous diseases with abnormal 
permeability barrier function, e.g., atopic dermatitis,21-23 senile 
xerosis,24 lamellar ichthyosis,25 Sjögren-Larsson syndrome25 and 
Dorfman-Chanarin syndrome.26 Moreover, recent findings in 
cutaneous diseases and their animal models have further sug-
gested the importance of acylCer for terrestrial mammalian sur-
vival. A mutant Elovl4-knock-in mouse, a model of a rare form 
of autosomal dominant Stargardt macular dystrophy (STGD3), 
which lacks normal VLCFA generation due to a single 5 bp dele-
tion coded ER retention signal,27 results in the failure to form FA 
elongation complex. The homozygous mutant Elovl4 knock-in 
mouse lacks both acylCer and normal lamellar membranes, and 
displays abnormal lamellar body contents and postnatal lethal-
ity within 4 hrs due to excess water loss.28,29 Elovl4-null mice 
also show similar features.30 Whereas VLCFA are contained in 
distribution and distinct substrate specificities. Further details of 
ELOVLs are described in the next section (see below).
(2) Reduction (2nd Step). 3-ketoacyl-CoA reductase (KAR), 
which has a homologous relationship with the short chain dehy-
drogenase superfamily, catalyzes 3-ketoacyl-CoA to 3-hydroxy-
acyl-CoA. The gene encoding this enzyme is a homologue of 
yeast Ybr159p.9
(3) Dehydration (3rd Step). Four 3-hydroxyacyl-CoA dehy-
dratases (HACD) that catalyze the dehydration of the 3-hydroxy-
acyl-CoA have been characterized in mammals. Both HACD1 
and HACD2 have similarities in their sequences to yeast Phs. 
Like ELOVLs, four HASDs show tissue specific expression 
profiles.10 Although substrate specificities of HACD have not 
been completely elucidated, HACD2 and HACD3 are ubiqui-
tously expressed, and the other two HACD levels, HACD1 and 
HACD4, are high in heart and leukocyte in humans,10 suggest-
ing that appropriate HACDs are likely utilized for specific FA 
elongation in combination with ELOVL expressed in the same 
tissue. Yet, expression profile on HACD in epidermis has not 
been characterized.
(4) Reduction (4th Step). The trans-2,3-enoyl-CoA reductase 
(TER) that catalyzes 3-hydroxyacyl-CoA to fatty acyl-CoA, is 
32% identical to the yeast trans-2,3-enoyl-CoA reductase and 
a homologue of Yeast Tsc13p.9 Although all other FA elonga-
tion enzymes (step 1 through 3) contain a ER retention motif 
(KKXX), TER does not have such motif.9 In contrast to ELOVLs 
and HACDs, only two reductases (KAR and TER) that account 
for the second and last step of elongation have been identified. It 
is unclear whether these identified reductases serve to reduce any 
chain lengths of 3-ketoacyl-CoA or 3-hydroxyacyl-CoA.
VLCFA in Tissues
VLCFA (C26-40) are present as saturated, monounsaturated 
and polyunsaturated forms. In contrast to FA containing hydro-
carbon chain lengths of 16–22, which are widely distributed in 
most living organisms including mammals, VLCFA (C26-40) 
are found in limited species and tissues mainly in yeasts, plants 
(seed oils, plant waxes, cutin, suberin) and mammals (brain, 
retina, skin, hair, testis and spermatozoa). Brain and retina con-
tain VLCFA-PUFA in phosphatidylcholine,4,11 while VLCFA are 
contained in Cer, glycosphingolipids and sphingomyelins (SM) 
in spermatozoa.12,13 VCLFA have been shown predominantly in 
Cer and glucosylceramide (GlcCer), but trace levels are in SM, 
in epidermis.14
ELOVL
ELOVL have been the most characterized enzymes in the FA 
elongation complex, including substrate specificities and expres-
sion profile in tissues. Pertinently, physiological and pathologi-
cal roles of certain ELOVL in mammals, including in skin, have 
been elucidated. Hence, ELOVLs are further discussed in this 
review below.
Seven mammalian homologues (ELOVL1-7) of the yeast 
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VLCFA synthesis.  Elovl3-,  Elovl4-,  Elovl5-,37  Elovl6-null 
mice,38 and mutant Elov4 knock-in mice have been generated to 
date (November 2010). Only homozygous Elovl4-null and Elov4 
knock-in mice are lethal due to epidermal permeability barrier 
defects.28-30 VLCFA containing hydrocarbon chain length of 
28 levels do not differ in epidermis of normal Wt mice and of 
homozygous mutant ELOVL4 knock-in mice that lack acyl-
Cer production.28 However, since increased VLCFA containing 
hydrocarbon chain length of 26 and absence of >C28 are evident 
in epidermis from homozygous mutant Elovl4-knock-in mice,28 
ELOVL4 is responsible for VLCFA being required for acylCer 
amide-linked FA production.28 Skin phenotypes and epidermal 
Cer profiles of Elovl5-null (-/-),37 and Elovl6-null38 mice are not 
reported, while those mice are not neonatal lethal. Although 
Elovl3-null mice show normal epidermal permeability barrier 
function at basal condition and contain normal levels of acylCer, 
a barrier recovery was delayed following acute barrier perturba-
tion,39 suggesting that ELOVL3 function is not compensated by 
other ELOVLs. Therefore, both ELOVL1, 3, 6 and/or 7 can be 
involved in generate substrate of VLCFA catalyzed by ELOVL4, 
and ELOVL1, 3, 6 and/or 7, expressed in skin, can compensate 
each other to synthesize VLCFA, if any of them are defective.
Cer synthesis. Cer are synthesized primarily at the endoplas-
mic reticulum (ER). Sphingoid base is generated by both De 
novo pathway and Salvage (or recycle) pathway. De novo pathway 
L-serine and palmitoyl-CoA are condensed by serine palmitoyl-
transferase to form 3-ketosphinganine, followed by its reduction 
to sphinganine by 3-ketosphinganine reductase, and subsequent 
N-acylation of sphinganine by Cer synthase(s).40 Six isoforms 
of Cer synthase (CerS 1–6) preferentially utilize selected car-
bon chain lengths of acyl-CoA as substrate.41 CerS 3, which is 
acylCer and acylGlcCer in epi-
dermis, part of VLCFA is in other 
Cer species as well as free VLCFA. 
However, most recent studies fur-
ther support the essential role of 
acylCer in barrier formation and 
function. Deficiencies of both 
acylCer and bound ω-OH Cer 
were found in the SC of a patient 
with Dorfman-Chanarin syn-
drome, an autosomal recessive, 
neutral lipid storage disorder with 
ichthyosis (NLSDI), display-
ing an abnormal permeability 
barrier function due to loss-of-
function mutations in CGI-58 
(α/β-hydrolase domain-containing 
protein 5) [ABHD5] (that codes a 
cofactor required for triacylglyc-
eride lipase).26 CGI-58 deficient 
mice, a model of Dorfman-
Chanarin syndrome, also dis-
play both acylCer and bound 
ω-OH Cer deficiencies in parallel 
with a neonatal lethal skin bar-
rier defect31 (c.f. see in the review of this series by Dr. Rudolf 
Zechner). Although triacylglyceride accumulation in the SC32 
could also contribute to altered lamellar membrane structures, 
VLCFA generation is not affected by lacking CGI-58 func-
tion, suggesting that acylCer rather than other Cer containing 
VLCFA and/or free VFCFA are more critical lipid species. The 
insights of Dorfman-Chanarin syndrome also led to elucidation 
of the synthetic pathway of acylCer (see next section). Finally, 
the ω-position of the amide-linked FA moiety of ω-OH Cer 
becomes covalently bound to the carboxy termini of cornified 
envelope proteins (primarily involucrin) on the external surface 
of the corneocyte, forming the corneocyte lipid envelope (i.e., 
bound form of ω-OH Cer.) (reviewed in ref. 33) Although the 
function of the corneocyte lipid envelope has not been com-
pletely defined, it has been proposed that it serves as a scaffold 
for the deposition of extracellular lamellar bilayers.34 Hence, 
taken together with these findings, acylCer is a more physiologi-
cally important lipid species containing VLCFA compared with 
other Cer species and/or free VLCFA in epidermis.
AcylCer Formation
AcylCer synthesis occurs in the late stages of keratinocyte dif-
ferentiation.35,36 In human epidermis, three distinct acylCer spe-
cies which contain a different sphingoid base; i.e., sphingosine, 
6-hydroxy sphingosine and 4-hydroxysphinganine (or phyto-
sphingosine), for the acylCer species Cer 1 (EOS), Cer 4 (EOH), 
and Cer 9 (EOP), respectively33 (Fig. 1), have been identified. 
AcylCer formation requires unique synthetic steps, including 
VLCFA synthesis, ω-hydroxylation, and ω-O-esterification   
(Fig. 2).
Figure 1. Structures of AcylCer. Abbreviation for Cer structures are according to robson et al. and Motta 
et al. N, A and EO indicate amide-linked FA species: N, non-OH FA; and EO, ω-O-esterified FA. A, S, P and H 
indicate sphingoid base structures: S, sphingosine (or sphingenine); P, 4-hydroxysphinganine (or phy-
tosphingosine); and H, 6-hydroxysphingosine (or 6-hydroxysphingenine). Late stages of differentiated 
keratinocytes produce heterogeneous Cer molecules (at least ten species) due to different combination of 
sphingoid base and amide-linked FA species, while acylCer are unique to the epidermis.68  Dermato-Endocrinology  volume 3 issue 2
ω-O-FA esterification. While 
it is suggested that FA derived 
from triacylglyceride is utilized 
in the ω-O-esterification step to 
form acylCer,47 both triacylglycer-
ide, linoleate and acylCer content 
decline in acyl-CoA:diacylglycerol 
acyltransferase-2 (DGAT2)-
deficient mice in parallel with 
abnormal permeability barrier.48 
Moreover, as described above, 
recent studies further suggest that 
linoleate produced by the lypolysis 
of triacylglyceride, which is facili-
tated by CGI-58, provides FA that 
is utilized for ω-O-esterification 
leading to acylCer formation.26,31
Regulation of ELOVL 
Expression
Increased in both acylCer/acyl-
GlcCer generation36 and ELOVL4 
mRNA expression occur late in kera-
tinocyte differentiation (Y. Uchida   
et al. unpublished data). Gene silenc-
ing of vitamin D receptor and its 
coactivator SRC (steroid receptor 
coactivator) 2 and SRC3 decreased 
both ELOVL3 and ELOVL4 mRNA 
expression in cultured primary KC.49 
Since vitamin D receptor stimula-
tion increased KC differentiation, it 
remains to be resolved whether the 
vitamin D receptor directly binds to 
promoter regions of ELOVL3 and/
or ELOVL4. The regulatory mecha-
nisms of other ELOVLs in epidermis 
have not been elucidated.
Similar to epidermis, a few studies about the regulation of 
ELOVL expression have been demonstrated in selected extra-
cutaneous tissues as below. ELOVL1, ELOVL3 and ELOVL6 
expression increase after cold stress followed by heat generation 
to maintain body temperature in murine brown adipose tissues.50 
Nutritional status also affects FA metabolism, including changes 
in ELOVL expression.51 These alterations of ELOVL expression 
are due to transcriptional levels. ELOVL1 and ELOVL6 mRNA 
expressions are upregulated by the nuclear liver X receptor (LXR)-
sterol regulatory element-binding protein (SREBP-1)-mediated 
mechanism cultured brown adipocytes.50 In contrast, ELOVL3 
mRNA expression is downregulated by LXR-SREBP-1 mechanism 
and upregulated by adrenergic stimulation.50 Recent studies also 
characterized the adrenergic mechanism for ELOVL3 as synergis-
tically enhanced by the peroxisome proliferator-activated receptor 
(PPAR)α activation.52 ELOVL5 mRNA expression is increased by 
LXRα-SREBP-1c pathway and downregulated by PUFA.53
expressed in skin and testis and has broad substrate specificity, 
including VLCFA, appears to be involved in acylCer formation.42 
Following N-acylation, the sphinganine moiety is either desatu-
rated to a sphingenine (or sphingosine) backbone by desaturase-1 
(DES-1) or hydroxylated to 4-OH sphinganine (phytosphingo-
sine),43 by desaturase-2 (or DES-2) or to 6-OH sphingosine by 
an enzyme which has not yet been identified.44 In addition to de 
novo sphingoid base synthesis (through serine palimitoyltrans-
ferase), salvage pathway (or sphingosine recycling) also occurs as 
GlcCer and SM are hydrolyzed to Cer, followed by hydrolysis to 
sphingoid base and FA by ceramidases.45 Generated sphingoid 
base can then be reutilized as substrates for Cer formation.36
FA  ω-hydroxylation. Prior studies indicate that blockade 
of FA ω-hydroxylation using a specific inhibitor of P-450-type 
4 isoforms, aminobenzoltriazol, causes a decrease in ω-OH 
Cer production and CLE formation accompanied by a barrier 
abnormality,46 suggesting that P-450-type 4 isoform appears to 
account for FA ω-hydroxylation.
Figure 2. Updated most likely pathway for acylCer formation (November 2010). AcylCer formation re-
quires unique biochemical steps, which include vLFA synthesis, ω-hydroxylation and ω-O-esterification. 
ELOvL4 and a cytochrome P-450 enzyme account for vLFA synthesis and ω-hydroxylation, respectively. 
Linoleic acid, an essential FA, is a predominant lipid species in ω-O-esterified FA. CE, cornified envelope; 
LA, linoleic acid; Sp, sphingoid base; and DGAT2, acylCoA:diacylglycerol acyltransferase 2.www.landesbioscience.com Dermato-Endocrinology  69
Veterans Affairs Medical Center and University of California,   
San Francisco, CA USA) are gratefully acknowledged for criti-
cal discussions about the metabolism and roles of acylceramide 
in skin. These studies were supported by a National Institutes of 
Health Grant AR 051077.
Acknowledgements
The author thanks Dr. Yukiko Mizutani (Hokkaido University, 
Sapporo, Japan) for helpful input to the manuscript and also 
thanks Ms. Joan Wakefield for editorial assistance. Drs. Peter 
M. Elias and Walter M. Holleran (Department of Dermatology, 
References
1.  Elias PM, Menon GK. Structural and lipid biochemical 
correlates of the epidermal permeability barrier. Adv Lipid 
Res 1991; 24:1-26.
2.  Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. 
Common loss-of-function variants of the epidermal barrier 
protein filaggrin are a major predisposing factor for atopic 
dermatitis. Nat Genet 2006; 38:441-6.
3.  Aveldano MI, Sprecher H. Very long chain (C24 to C36) 
polyenoic fatty acids of the n-3 and n-6 series in dipolyun-
saturated phosphatidylcholines from bovine retina. J Biol 
Chem 1987; 262:1180-6.
4.  Sharp P, Johnson D, Poulos A. Molecular species of 
phosphatidylcholine containing very long chain fatty acids 
in human brain: enrichment in X-linked adrenoleukodys-
trophy brain and diseases of peroxisome biogenesis brain. J 
Neurochem 1991; 56:30-7.
5.  Grogan WM. Metabolism of arachidonate in rat testis: 
characterization of 26–30 carbon polyenoic acids. Lipids 
1984; 19:341-6.
6.  Poulos A, Sharp P, Johnson D, Easton C. The occurrence 
of polyenoic fatty acids with greater than 22 carbon atoms 
in mammalian spermatozoa. Biochem J 1986; 240:891-5.
7.  Leonard AE, Pereira SL, Sprecher H, Huang YS. Elongation 
of long-chain fatty acids. Prog Lipid Res 2004; 43:36-54.
8.  Jakobsson A, Westerberg R, Jacobsson A. Fatty acid elon-
gases in mammals: their regulation and roles in metabo-
lism. Prog Lipid Res 2006; 45:237-49.
9.  Moon YA, Horton JD. Identification of two mammalian 
reductases involved in the two-carbon fatty acyl elongation 
cascade. J Biol Chem 2003; 278:7335-43.
10.  Ikeda M, Kanao Y, Yamanaka M, Sakuraba H, Mizutani 
Y, Igarashi Y, et al. Characterization of four mammalian 
3-hydroxyacyl-CoA dehydratases involved in very long-
chain fatty acid synthesis. FEBS Lett 2008; 582:2435-40.
11.  Aveldano MI. A novel group of very long chain polyenoic 
fatty acids in dipolyunsaturated phosphatidylcholines from 
vertebrate retina. J Biol Chem 1987; 262:1172-9.
12.  Furland NE, Oresti GM, Antollini SS, Venturino A, 
Maldonado EN, Aveldaño MI. Very long-chain poly-
unsaturated fatty acids are the major acyl groups of 
sphingomyelins and ceramides in the head of mammalian 
spermatozoa. J Biol Chem 2007; 282:18151-61.
13.  Rabionet M, van der Spoel AC, Chuang CC, von 
Tümpling-Radosta B, Litjens M, Bouwmeester D, et 
al. Male germ cells require polyenoic sphingolipids with 
complex glycosylation for completion of meiosis: a link to 
ceramide synthase-3. J Biol Chem 2008; 283:13357-69.
14.  Uchida Y, Hara M, Nishio H, Sidransky E, Inoue S, 
Otsuka F, et al. Epidermal sphingomyelins are precursors 
for selected stratum corneum ceramides. J Lipid Res 2000; 
41:2071-82.
15.  Ohno Y, Suto S, Yamanaka M, Mizutani Y, Mitsutake S, 
Igarashi Y, et al. ELOVL1 production of C24 acyl-CoAs is 
linked to C24 sphingolipid synthesis. Proc Natl Acad Sci 
USA 2010; 107:18439-44.
16.  Burr GO, Burr MM. On the Nature and Role of 
Fatty Acids Essential in Nutrition. J Biol Chem 1930; 
86:587-621.
17.  Gray GM, White RJ, Majer JR. 1-(3'-O-acyl)-beta-
glucosyl-N-dihydroxypentatriacontadienoylsphingosine, 
a major component of the glucosylceramides of pig 
and human epidermis. Biochim Biophys Acta 1978; 
528:127-37.
18.  Wertz PW, Downing DT. Ceramides of pig epidermis: 
structure determination. J Lipid Res 1983; 24:759-65.
19.  Bowser PA, Nugteren DH, White RJ, Houtsmuller UM, 
Prottey C. Identification, isolation and characterization of 
epidermal lipids containing linoleic acid. Biochim Biophys 
Acta 1985; 834:419-28.
20.  Bouwstra JA, Ponec M. The skin barrier in healthy and 
diseased state. Biochim Biophys Acta 2006; 1758:2080-95.
21.  Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, 
Hidano A. Decreased level of ceramides in stratum cor-
neum of atopic dermatitis: an etiologic factor in atopic dry 
skin? J Invest Dermatol 1991; 96:523-6.
22.  Yamamoto A, Serizawa S, Ito M, Sato Y. Stratum cor-
neum lipid abnormalities in atopic dermatitis. Archives 
for Dermatological Research. Archiv fur Dermatologische 
Forschung 1991; 283:219-23.
23.  Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide 
and cholesterol composition of the skin of patients with 
atopic dermatitis. Acta Dermato-Venereologica 1998; 
78:27-30.
24.  Rogers J, Harding C, Mayo A, Banks J, Rawlings A. 
Stratum corneum lipids: the effect of ageing and the sea-
sons. Arch Dermatol Res 1996; 288:765-70.
25.  Paige DG, Morse-Fisher N, Harper JI. Quantification of 
stratum corneum ceramides and lipid envelope cerami-
des in the hereditary ichthyoses. Br J Dermatol 1994; 
131:23-7.
26.  Uchida Y, Cho Y, Moradian S, Kim J, Nakajima 
K, Crumrine D, et al. Neutral lipid storage leads to 
acylceramide deficiency, likely contributing to the 
pathogenesis of Dorfman-Chanarin syndrome.   
J Invest Dermatol 2010; 130:2497-9.
27.  Zhang K, Kniazeva M, Han M, Li W, Yu Z, Yang Z, et al. 
A 5 bp deletion in ELOVL4 is associated with two related 
forms of autosomal dominant macular dystrophy. Nat 
Genet 2001; 27:89-93.
28.  Vasireddy V, Uchida Y, Salem N Jr, Kim SY, Mandal MN, 
Reddy GB, et al. Loss of functional ELOVL4 depletes very 
long-chain fatty acids (≥C28) and the unique {omega}-O-
acylceramides in skin leading to neonatal death. Hum Mol 
Genet 2007; 16:471-82.
29.  McMahon A, Butovich IA, Mata NL, Klein M, Ritter R 
3rd, Richardson J, et al. Retinal pathology and skin barrier 
defect in mice carrying a Stargardt disease-3 mutation in 
elongase of very long chain fatty acids-4. Mol Vis 2007; 
13:258-72.
30.  Li W, Sandhoff R, Kono M, Zerfas P, Hoffmann V, Ding 
BC, et al. Depletion of ceramides with very long chain fatty 
acids causes defective skin permeability barrier function, 
and neonatal lethality in ELOVL4 deficient mice. Int J Biol 
Sci 2007; 3:120-8.
31.  Radner FP, Streith IE, Schoiswohl G, Schweiger M, 
Kumari M, Eichmann TO, et al. Growth retardation, 
impaired triacylglycerol catabolism, hepatic steatosis and 
lethal skin barrier defect in mice lacking comparative 
gene identification-58 (CGI-58). J Biol Chem 2010; 
285:7300-11.
32.  Ujihara M, Nakajima K, Yamamoto M, Teraishi M, 
Uchida Y, Akiyama M, et al. Epidermal triglyceride 
levels are correlated with severity of ichthyosis in Dorfman-
Chanarin syndrome. J Dermatol Sci 2010; 57:102-7.
33.  Uchida Y, Holleran WM. Omega-O-acylceramide, a lipid 
essential for mammalian survival. J Dermatol Sci 2008; 
51:77-87.
34.  Wertz PW, Madison KC, Downing DT. Covalently bound 
lipids of human stratum corneum. J Invest Dermatol 1989; 
92:109-11.
35.  Uchida Y, Behne M, Quiec D, Elias PM, Holleran WM. 
Vitamin C stimulates sphingolipid production and mark-
ers of barrier formation in submerged human keratinocyte 
cultures. J Invest Dermatol 2001; 117:1307-13.
36.  Hamanaka S, Nakazawa S, Yamanaka M, Uchida Y, 
Otsuka F. Glucosylceramide Accumulates Preferentially 
in Lamellar Bodies in Differentiated Keratinocytes. Br J 
Dermatol 2005; 152:426-34.
37.  Moon YA, Hammer RE, Horton JD. Deletion of ELOVL5 
leads to fatty liver through activation of SREBP-1c in mice. 
J Lipid Res 2009; 50:412-23.
38.  Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, 
Yamamoto T, et al. Crucial role of a long-chain fatty acid 
elongase, Elovl6, in obesity-induced insulin resistance. Nat 
Med 2007; 13:1193-202.
39.  Westerberg R, Tvrdik P, Undén AB, Månsson JE, Norlén 
L, Jakobsson A, et al. Role for ELOVL3 and fatty acid 
chain length in development of hair and skin function. J 
Biol Chem 2004; 279:5621-9.
40.  Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do 
Lasses (longevity assurance genes) become CerS (ceramide 
synthases)?: Insights into the regulation of ceramide synthe-
sis. J Biol Chem 2006; 281:25001-5.
41.  Holleran WM, Takagi Y, Uchida Y. Epidermal sphingo-
lipids: Metabolism, function and role(s) in skin disorders. 
FEBS Letters 2006; 23:5456-66.
42.  Mizutani Y, Mitsutake S, Tsuji K, Kihara A, Igarashi Y. 
Ceramide biosynthesis in keratinocyte and its role in skin 
function. Biochimie 2009; 91:784-90.
43.  Ternes P, Franke S, Zähringer U, Sperling P, Heinz E. 
Identification and characterization of a sphingolipid delta 
4-desaturase family. J Biol Chem 2002; 277:25512-8.
44.  Stewart ME, Downing DT. A new 6-hydroxy-4-sphin-
genine-containing ceramide in human skin. J Lipid Res 
1999; 40:1434-9.
45.  Hamanaka S, Nakazawa S, Yamanaka M, Uchida Y, 
Otsuka F. Glucosylceramide accumulates preferentially 
in lamellar bodies in differentiated keratinocytes. Br J 
Dermatol 2005; 152:426-34.
46.  Behne M, Uchida Y, Seki T, de Montellano PO, Elias PM, 
Holleran WM. Omega-hydroxyceramides are required for 
corneocyte lipid envelope (CLE) formation and normal 
epidermal permeability barrier function. J Invest Dermatol   
2000; 114:185-92.
47.  Wertz PW, Downing DT. Metabolism of linoleic acid in 
porcine epidermis. J Lipid Res 1990; 31:1839-44.
48.  Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold 
KR, Elias PM, et al. Lipopenia and skin barrier abnor-
malities in DGAT2-deficient mice. J Biol Chem 2004; 
279:11767-76.
49.  Oda Y, Uchida Y, Moradian S, Crumrine D, Elias 
PM, Bikle DD. Vitamin D Receptor and Coactivators 
SRC2 and 3 Regulate Epidermis-Specific Sphingolipid 
Production and Permeability Barrier Formation. J Invest 
Dermatol 2008; 129:1367-78.
50.  Jakobsson A, Jorgensen JA, Jacobsson A. Differential 
regulation of fatty acid elongation enzymes in brown adi-
pocytes implies a unique role for Elovl3 during increased 
fatty acid oxidation. Am J Physiol Endocrinol Metab 
2005; 289:517-26.
51.  Wang Y, Botolin D, Christian B, Busik J, Xu J, Jump DB. 
Tissue-specific, nutritional and developmental regulation 
of rat fatty acid elongases. J Lipid Res 2005; 46:706-15.
52.  Jorgensen JA, Zadravec D, Jacobsson A. Norepinephrine 
and rosiglitazone synergistically induce Elovl3 expression in 
brown adipocytes. Am J Physiol Endocrinol Metab 2007; 
293:1159-68.
53.  Qin Y, Dalen KT, Gustafsson JA, Nebb HI. Regulation 
of hepatic fatty acid elongase 5 by LXRalpha-SREBP-1c. 
Biochim Biophys Acta 2009; 1791:140-7.
54.  Robson KJ, Stewart ME, Michelsen S, Lazo ND, Downing 
DT. 6-Hydroxy-4-sphingenine in human epidermal 
ceramides. J Lipid Res 1994; 35:2060-8.
55.  Motta S, Monti M, Sesana S, Caputo R, Carelli S, Ghidoni 
R. Ceramide composition of the psoriatic scale. Biochim 
Biophys Acta 1993; 1182:147-51.